Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
7.90
+0.04 (0.57%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Arcus Biosciences Employees
Arcus Biosciences had 627 employees as of December 31, 2024. The number of employees increased by 50 or 8.67% compared to the previous year.
Employees
627
Change (1Y)
50
Growth (1Y)
8.67%
Revenue / Employee
$411,483
Profits / Employee
-$451,356
Market Cap
833.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
RCUS News
- 9 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 16 days ago - Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - Seeking Alpha
- 7 weeks ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update - Business Wire
- 2 months ago - Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering - Business Wire
- 2 months ago - Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock - Business Wire
- 2 months ago - New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer - Business Wire
- 2 months ago - Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium - Business Wire